Literature DB >> 31625195

Identification SYT13 as a novel biomarker in lung adenocarcinoma.

Liyan Zhang1, Bijun Fan1, Yu Zheng1, Yueyan Lou1, Yongqi Cui1, Ke Wang2, Tiancheng Zhang2, Xiaoming Tan1.   

Abstract

Synaptotagmins are a class of proteins that play an important role in the secretion of neurotransmitters by synaptic vesicles. However, recent studies have shown that members of this family also have a certain function in the development of tumors. In this study, we first identified through The Cancer Genome Atlas data analyzed that a novel synaptotagmin, SYT13, was closely related to the prognosis of lung adenocarcinoma, but was not significantly correlated with the prognosis of lung squamous cell carcinoma. Then we knocked down the expression of SYT13 gene in lung adenocarcinoma cell lines A549 and H1299, and successfully induced decreased proliferation and clonality of lung adenocarcinoma cell lines, and observed cell cycle arrest and apoptosis enhancement in both cell lines. In addition, we detected the migration ability of SYT13 knockdown lung adenocarcinoma cell lines by the cell scratch test and the transwell test. Interestingly, there was a decreased migration ability of SYT13 knockdown in H1299 cells even though there was no significant difference in the migration of A549 cells. These results demonstrate that SYT13 plays an important role in the development of lung adenocarcinoma, which deepens our understanding of the mechanism of lung adenocarcinoma development and provides new possibilities for targeted therapy of lung adenocarcinoma.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  SYT13; lung adenocarcinoma; synaptotagmins; targeted therapy

Mesh:

Substances:

Year:  2019        PMID: 31625195     DOI: 10.1002/jcb.29224

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

1.  Synaptotagmin-13 Is a Neuroendocrine Marker in Brain, Intestine and Pancreas.

Authors:  Marta Tarquis-Medina; Katharina Scheibner; Ismael González-García; Aimée Bastidas-Ponce; Michael Sterr; Jessica Jaki; Silvia Schirge; Cristina García-Cáceres; Heiko Lickert; Mostafa Bakhti
Journal:  Int J Mol Sci       Date:  2021-11-20       Impact factor: 5.923

2.  Synaptotagmin 13 Is Highly Expressed in Estrogen Receptor-Positive Breast Cancer.

Authors:  Takahiro Ichikawa; Masahiro Shibata; Takahiro Inaishi; Ikumi Soeda; Mitsuro Kanda; Masamichi Hayashi; Yuko Takano; Dai Takeuchi; Nobuyuki Tsunoda; Yasuhiro Kodera; Toyone Kikumori
Journal:  Curr Oncol       Date:  2021-10-12       Impact factor: 3.677

3.  Synaptotagmin-13 orchestrates pancreatic endocrine cell egression and islet morphogenesis.

Authors:  Mostafa Bakhti; Aimée Bastidas-Ponce; Sophie Tritschler; Oliver Czarnecki; Marta Tarquis-Medina; Eva Nedvedova; Jessica Jaki; Stefanie J Willmann; Katharina Scheibner; Perla Cota; Ciro Salinno; Karsten Boldt; Nicola Horn; Marius Ueffing; Ingo Burtscher; Fabian J Theis; Ünal Coskun; Heiko Lickert
Journal:  Nat Commun       Date:  2022-08-04       Impact factor: 17.694

Review 4.  Potential roles of synaptotagmin family members in cancers: Recent advances and prospects.

Authors:  Huandan Suo; Nan Xiao; Kewei Wang
Journal:  Front Med (Lausanne)       Date:  2022-08-08

5.  Comprehensive analysis on the expression profile and prognostic values of Synaptotagmins (SYTs) family members and their methylation levels in gastric cancer.

Authors:  Mei-Feng Yang; Xing-Xing Long; Hong-Sai Hu; Yu-Ling Bin; Xuan-Ming Chen; Ben-Hua Wu; Quan-Zhou Peng; Li-Sheng Wang; Jun Yao; De-Feng Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.